Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11422616 | 0.90 | LMNA (0.41) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL16308865 | 0.87 | GABRA1 (0.41) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL15978284 | 0.85 | GABRA1 (0.39) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL31017692 | 0.81 | GABRA1 (0.44) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL11048642 | 0.81 | GABRA1 (0.44) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL1335807 | 0.81 | GABRA1 (0.48) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL14924905 | 0.80 | LMNA (0.41) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL15044960 | 0.79 | GABRA1 (0.35) | GABRA1GABRB1LMNAPOLBGAA | |
| SCHEMBL5530284 | 0.79 | GABRA1 (0.45) | GABRA1GABRB1LMNAGAATRPA1 | |
| SCHEMBL5529593 | 0.79 | LMNA (0.53) | GABRA1GABRB1LMNAGAATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022389-B2 | Prophylactic or therapeutic drug for constipation | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20150374735-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR CONSTIPATION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9161945-B2 | 4-isopropyl-6-methoxyphenyl glucitol compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-20130165645-A1 | 4-ISOPROPYL-6-METHOXYPHENYL GLUCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-06-27 | — | — | US | disclosed |
| US-8466113-B2 | 4-isopropylphenyl glucitol compounds as SGLT1 inhibitors | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110306759-A1 | 4-ISOPROPYLPHENYL GLUCITOL COMPOUNDS AS SGLT1 INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165645-A1 | 4-ISOPROPYL-6-METHOXYPHENYL GLUCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A4 | GABRA1 2128/4885GABRB1 1517/4885LMNA 4212/4885 |
| US-20150374735-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR CONSTIPATION | SLC5A1, SLC5A2, SLC10A2 | GABRA1 1151/4885GABRB1 944/4885LMNA 3968/4885 |
| US-20110306759-A1 | 4-ISOPROPYLPHENYL GLUCITOL COMPOUNDS AS SGLT1 INHIBITORS | SLC5A1, SLC5A2, SLC2A4 | GABRA1 2173/4885GABRB1 1584/4885LMNA 4286/4885 |
| US-10022389-B2 | Prophylactic or therapeutic drug for constipation | SLC5A1, SLC5A2, SLC10A2 | GABRA1 1151/4885GABRB1 944/4885LMNA 3968/4885 |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | GABRA1 1792/4885GABRB1 1657/4885LMNA 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.